PMGC Holdings (ELAB)
NASDAQ:ELAB
Want to see ELAB full AI Analyst Report?
ELAB Stock Chart & Stats
$1.55
-$0.19(-8.12%)
At close: 4:00 PM EST
$1.55
-$0.19(-8.12%)
Day’s Range― - ―
52-Week Range$1.62 - $309.12
Previous CloseN/A
Volume180.10K
Average Volume (3M)89.87K
Market Cap
$8.09M
Enterprise Value-$3.29M
Total Cash (Recent Filing)$15.09M
Total Debt (Recent Filing)$7.96M
Price to Earnings (P/E)―
Beta2.56
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,543,751
10 Day Avg. Volume35,159
30 Day Avg. Volume89,868
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)4.90
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.41
Enterprise Value/Revenue-2.59
Enterprise Value/Gross Profit-20.40
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Long-term Aerospace & Defense Supply ContractsMulti-year supply agreements and documented performance commitments create durable revenue visibility, raise switching costs, and support margin stability. For a precision manufacturing roll-up, recurring defense contracts reduce volatility and underpin steady cash generation as certification and delivery histories accumulate.
Completed Acquisition Of A&B AerospaceAn accretive, bolt-on acquisition that retains management and operational continuity can immediately add revenue, improve consolidated gross profit, and bolster cash flow. Successful integration of such small, profitable targets supports PMGC’s roll-up strategy and long-term scale economics across aerospace supply chains.
Expanded IP For Muscle‑health Drug EL-22Strengthening patent coverage around EL-22 builds a durable competitive moat for NorthStrive’s lead asset, enabling future licensing, partnership or commercialization paths. Robust IP raises optionality and long-term asset value independent of near-term cash burn, supporting strategic diversification of PMGC’s holdings.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained free‑cash‑flow burn forces ongoing reliance on external financing and limits capacity to invest organically or fund integration costs. Over months this heightens liquidity risk, increases financing costs, and makes the firm vulnerable to disruptions if equity facilities or reserved capital become constrained.
Rising Leverage And Concentrated Secured ClaimsMaterial increase in debt and the use of secured equity facilities concentrate creditor claims over subsidiaries and reduce financial flexibility. Higher leverage raises fixed obligations, restricts strategic choices, and could complicate future M&A or covenant compliance during protracted cash burn periods.
Deep Unprofitability And Thin Gross Margins Despite GrowthRevenue growth has not translated into sustainable profitability: thin gross margins and outsized operating losses indicate structural cost or pricing gaps. Without demonstrated margin recovery or scale-driven efficiency, earnings will remain negative and the business will continue to consume capital rather than generate surplus cash.
PMGC Holdings News
ELAB FAQ
What was PMGC Holdings’s price range in the past 12 months?
PMGC Holdings lowest stock price was $1.62 and its highest was $309.12 in the past 12 months.
What is PMGC Holdings’s market cap?
PMGC Holdings’s market cap is $8.09M.
When is PMGC Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PMGC Holdings’s earnings last quarter?
Currently, no data Available
Is PMGC Holdings overvalued?
According to Wall Street analysts PMGC Holdings’s price is currently Overvalued.
Does PMGC Holdings pay dividends?
PMGC Holdings does not currently pay dividends.
What is PMGC Holdings’s EPS estimate?
PMGC Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PMGC Holdings have?
PMGC Holdings has 4,543,751 shares outstanding.
What happened to PMGC Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PMGC Holdings?
Currently, no hedge funds are holding shares in ELAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PMGC Holdings
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
CNS Pharmaceuticals
―